Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice

Table 3 Grade 5 events in both the arms IMBrave 150 trial

Atezolizumab and bevacizumab (n = 15), grade 5 adverse events	Sorafenib (n = 9), grade 5 adverse events
Gastrointestinal Haemorrhage (3)	Death (2)
Pneumonia (2)	Hepatic cirrhosis (2)
Empyema, gastric ulcer perforation, abnormal hepatic function, liver injury, multi-organ dysfunction syndrome, esophageal varices haemorrhage, subarachnoid haemorrhage, respiratory distress, sepsis and cardiac arrest (1 in each patient)	Cardiac arrest, cardiac failure, general physical health deterioration, hepatitis E, peritoneal haemorrhage (1 in each patient)